Novothelium

Executive Summary

NovoThelium is a private biotechnology company developing a tissue-engineered matrix for nipple-areolar complex (NAC) regeneration following mastectomy. Founded in 2018 by biomedical engineers with personal connections to breast cancer, the company addresses the significant shortcomings of current nipple reconstruction techniques, which often result in poor aesthetics, loss of sensation, and long-term complications. Its core technology involves processing donor or autologous tissue to create a decellularized scaffold that enables repopulation with patient cells, aiming to regenerate a functional, sensate nipple. The company is based in Cambridge, Massachusetts, and operates in the biologics and tissue engineering sectors. While still in early stages with no disclosed funding or pipeline milestones, the product targets a clear unmet need in post-mastectomy reconstruction, with potential to improve quality of life for breast cancer survivors. However, limited public information suggests a high-risk profile typical of early-stage medical device/biologic companies.

Upcoming Catalysts (preview)

• TBDSeries A Financing Round40% success
• TBDPreclinical Proof-of-Concept Data Release50% success
• TBDFDA Pre-IND Meeting or Breakthrough Device Designation30% success